Secured around KRW 7.8 billion in cumulative investment and signed global export contracts valued at approximately KRW 7 billion
Finalized lead underwriter agreement for a 2028 IPO; Committed to job creation
[소셜밸류=박완규 기자] Imeditech, a resident company of Seoul Startup Hub Seongsu, has recently shown rapid growth, pursuing global expansion and an IPO.
According to Seoul Startup Hub, Imeditech is a medical device specialist that achieved 178% YoY sales growth this year. In fact, its monthly sales surged from KRW 400 million to KRW 700 million, enhancing both its profitability and business scale.
Nano-I by Imeditech is a portable nanofiber medical device that generates a nanofiber membrane, ensuring swift treatment. It maximizes effectiveness through non-contact treatment and provides convenience by the rapid spraying of nanofibers onto contoured and extensive surface.
Reliable technology has played a critical role in the company’s growth. The company bolstered its credibility by securing GMP and ISO certifications and aggressively expanded its market presence by attracting 20 new clients.
Building on its first export achievement in the second half of 2025, it has already proven its competitiveness in the global market by signing export contracts valued at KRW 7 billion over the next three years.
Along with its growth, the company is also receiving positive feedback from the investment community. In fact, Imeditech secured a Series A Bridge investment amounting to KRW 1.55 billion, gaining significant momentum for its future growth.
The company is implementing a phased roadmap to enhance its corporate value. Having recently finalized the agreement with its lead underwriter for an initial public offering (IPO), it is now poised to enter the capital market. It is currently concentrating on sound management to enhance corporate value, with the aim of going public by 2028.
Seoul Startup Hub, the Seoul Metropolitan Government’s policy implementation agency, has played a pivotal role in supporting the company’s growth to this stage.
Following its relocation to Seoul Startup Hub Seongsu, it secured a foothold in Seoul for its expansion into the metropolitan area. Then, it gained a significant momentum in building investment networks and identifying new business opportunities, hiring 17 new employees across diverse sectors including R&D, production, quality control and sales. As a result, it led to enhancing its organizational capabilities and ensuring the stability of its business operations.
Park Jun-gyu, the CEO of Imeditech, noted, “We laid the groundwork for global expansion through securing a foothold in Seoul with a strategic support from Seoul Startup Hub Seongsu. Building on our technology and investment, we aim to become a leading global innovator, introducing cutting-edge K-medical devices to the world following a successful IPO in 2028”.
Officials of Seoul Startup Hub said, “We plan to promote Seoul Startup Hub Seongsu as a hub for future strategic industries, such as Age-tech, IT and cultural content. We’re committed to providing full resources to promising Seoul-based startups, including Imeditech, to help them grow into global unicorns by offering customized promotion, investment matching and supports.”
[저작권자ⓒ 사회가치 공유 언론-소셜밸류. 무단전재-재배포 금지]
